论文部分内容阅读
Vicriviroc是先灵葆雅公司正在开发的抗HIV感染药,属于一种小分子的趋化因子受体CCR5拮抗剂,能显著抑制HIV-1进入宿主细胞,可与其它药物联合使用治疗嗜R5型HIV-1感染的病人。已有临床试验结果表明,在采用优化基础疗法(如利托那韦加另一种蛋白酶抑制剂)的同时使用vicriviroc(10
Vicriviroc is an anti-HIV drug under development by Schering-Plow and belongs to a small molecule chemokine receptor CCR5 antagonist that significantly inhibits the entry of HIV-1 into host cells for use in combination with other drugs to treat R5-type HIV-1 Infected patients. Clinical trials have shown that vicriviroc (10) is used in combination with optimized basal regimens (such as ritonavir plus another protease inhibitor)